Scarica l'app Stockscreener
14.47
0.98%
0.14
Pre-mercato:
14.30
-0.17
-1.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$14.33
Aprire:
$14.33
Volume 24 ore:
2.16M
Relative Volume:
0.97
Capitalizzazione di mercato:
$1.66B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.6913
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+5.85%
1M Prestazione:
+3.51%
6M Prestazione:
-3.47%
1 anno Prestazione:
+50.73%
Intervallo 1D:
$13.97
$14.65
Intervallo di 1 settimana:
$13.63
$14.69
Portata 52W:
$7.86
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.47 | 1.66B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia
Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN
H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia
H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa
Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan
Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga
Road to RAD: What to Expect - Dermatology Times
ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus
Arcutis Biotherapeutics director Heron buys $30,246 in stock By Investing.com - Investing.com India
Arcutis Biotherapeutics director Heron buys $30,246 in stock - Investing.com Australia
Where are the Opportunities in (ARQT) - news.stocktradersdaily.com
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQ - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast - GuruFocus
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - The Manila Times
Arcutis (ARQT) to Showcase New Data at 2025 RAD Conference | ARQT Stock News - GuruFocus
New Clinical Data: ZORYVE's Breakthrough 34-Week Skin Control for Children with Atopic Dermatitis - Stock Titan
Two Sigma Investments LP Cuts Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
H.C. Wainwright reiterates buy rating and $19 target on Arcutis stock - Investing.com
Transcript : Arcutis Biotherapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Nuveen Asset Management LLC Has $5.11 Million Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 5% – Time to Sell? - Defense World
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Ameriprise Financial Inc. Acquires 50,662 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcutis Biotherapeutics Inc Azioni (ARQT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Heron Patrick J | Director |
Jun 04 '25 |
Buy |
13.32 |
1,890 |
25,177 |
24,424 |
| Heron Patrick J | Director |
Jun 05 '25 |
Buy |
13.41 |
378 |
5,069 |
24,802 |
| Matsuda Masaru | See Remarks |
May 28 '25 |
Sale |
13.78 |
1,800 |
24,807 |
202,599 |
1.06%
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):